Medicinal compositions for concomitant use as anticancer agent

Details Medicinal compositions for concomitant use as anticancer agent Medicinal compositions for concomitant use as anticancer agent

A - Human Necessities

61

K

A61K 31/404 (2006.01) A61K 31/24 (2006.01) A61K 31/337 (2006.01) A61K 31/407 (2006.01) A61K 31/4745 (2006.01) A61K 31/513 (2006.01) A61K 31/704 (2006.01) A61K 31/7068 (2006.01) A61P 35/00 (2006.01) C07D 209/08 (2006.01) C07D 209/30 (2006.01) C07D 231/56 (2006.01) C07D 235/06 (2006.01) C07D 471/04 (2006.01)

Patent

CA 2427617

The present invention provides a medicinal composition having an excellent antitumor activity. That is, it provides a medicinal composition comprising a sulfonamide compound, a sulfonate compound or a salt of them, which is represented by the following formula: (see formula above) (wherein ring A represents an aromatic ring which may have a substituent group; ring B represents a 6-membered unsaturated hydrocarbon ring which may have a substituent group etc.; ring C represents a 5-membered hetero-ring containing one or two nitrogen atoms, and the ring C may have a substituent group; W represents a single bond or -CH=CH-; X represents -NH- etc. ; and Y represents a carbon atom or a nitrogen atom; and Z represents -NH- etc.), particularly N-(3-chloro-1H-indol-7- yl)-4-sulfamoylbenzenesulfonamide or a salt thereof, combined with at least one substance selected from (1) irinotecan hydrochloride trihydrate; (2) mitomycin C; (3) 5-fluorouracil; (4) cisplatin; (5) gemcitabine hydrochloride; (6) doxorubicin; (7) taxol; and (8) a salt of the above-mentioned (1) to (7).

Compositions médicinales ayant un effet antitumoral remarquable et, notamment, compositions médicinales caractérisées en ce qu'elles contiennent des dérivés de sulfonamide ou des dérivés d'ester d'acide sulfonique représentés par la formule générale (I) ou leurs sels, et notamment N-(3-chloro-1H-indol-7-yl)-4-sulfamoylbenzenesulfonamide ou son sel, qui sont combinés avec au moins un élément sélectionné parmi ce qui suit (1) irinotecan hydrochlorure trihydrate, (2) mitomycine C, (3) 5-fluoruracil, (4) cisplatine, (5) hydrochlorure de gemcitabine, (6) doxorubicine, (7) Taxol et (8) des sels des composés (1-7) énumérés ci-dessus. Dans la formule (I), le noyau A représente un noyau aromatique éventuellement substitué, le noyau B représente un noyau d'hydrocarbyle insaturé à 6 éléments éventuellement substitué, etc.; le noyau C représente un hétérocycle à 5 éléments possédant 1 ou 2 atomes d'hydrogène, qui peuvent être substitués; W représente une liaison unique ou -CH=CH-; X représente -NH-, etc.; Y représente un atome de carbone ou un atome d'hydrogène; et Z représente -NH- etc.

Affiliated with

Also associated with

Rating

Medicinal compositions for concomitant use as anticancer agent does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Medicinal compositions for concomitant use as anticancer agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medicinal compositions for concomitant use as anticancer agent will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1991561